Aardvark Therapeutics (AARD) announced that it has established Ardia Therapeutics, a new wholly-owned U.S. subsidiary. Ardia will support development of a new dermatology pipeline focused on lead asset, DIA-615, a potential topical treatment for a variety of inflammatory skin diseases, including psoriasis. Bryan Jones, Ph.D., has been named Chief Executive Officer of Ardia and has transitioned out of his current role at Aardvark as Chief Operating Officer to lead Ardia.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics appoints Li as CBO, Sun as COO
- Aardvark Expands PWS Phase 3 Trial to Younger Children
- Aardvark announces FDA submission, IRB approval of amended trial protocol
- Undervalued Obesity Innovator: Justifying a Buy on Aardvark’s Dual Rare-Disease and Mainstream Metabolic Opportunity
- Aardvark Therapeutics initiated with a Buy at B. Riley